Breakthrough Zygomycosis after Voriconazole Treatment in Recipients of Hematopoietic Stem-Cell Transplants

Top Cited Papers
Publisher Website
Google Scholar
Abstract
The Food and Drug Administration (FDA) approved voriconazole for the treatment of invasive aspergillosis partly on the basis of data published in a report in the Journal, 1 which showed an improved clinical response and improved survival with voriconazole treatment as compared with a strategy of initial treatment with amphotericin B deoxycholate. In patients with neutropenia and persistent fever, the use of voriconazole as empirical therapy failed to fulfill criteria for noninferiority as compared with liposomal amphotericin B,2 and the results of that trial generated substantial discussion after the FDA declined approval of the drug for that indication.3 Nevertheless, the use of voriconazole has become common in the management of neutropenia and persistent fever, in the treatment of high-risk patients with pneumonia, and as prophylaxis in patients who are at risk for the development of invasive fungal infections. These uses of voriconazole are probably attributable to its lower overall toxicity, its ease of oral administration, and its broad antifungal spectrum, especially against aspergillus species.

This publication has 0 references indexed in Scilit: